In this study, we evaluated the efficacy of the PAK1 inhibitor IPA‐3 as well as the BCAT1 inhibitors gabapentin and BCATc inhibitor 2 in CLL. The gene discussed is BCAT1; the disease is B-cell chronic lymphocytic leukemia.